Delving into the Latest Updates on Maxacalcitol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1α, 25-dihydroxy-22-oxavitamin D3, 22-oxacalcitriol, 22-オキサカルシトリオール

+ [8]

Target

VDR

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [3]

Active Indication

PsoriasisImpetigoIchthyosis+ [3]

Inactive Indication-

Originator Organization

Chugai Pharmaceutical Co., Ltd.

Active Organization

Maruho Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

LTL Pharma Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (03 Jul 2000),

Hyperparathyroidism, Secondary

Regulation-

Login to view timeline

Structure

Molecular FormulaC26H42O4

InChIKeyDTXXSJZBSTYZKE-ZDQKKZTESA-N

CAS Registry103909-75-7

This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism. The main objective of this study is to demonstrate the efficacy of paricalcitol injection in reducing levels of parathyroid hormone without clinically significant hypercalcemia, compared to maxacalcitol injection.

Start Date01 May 2011

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Maxacalcitol

Login to view more data

100 Translational Medicine associated with Maxacalcitol

Login to view more data

100 Patents (Medical) associated with Maxacalcitol

Login to view more data

882

Literatures (Medical) associated with Maxacalcitol

01 Jan 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Utilizing erythrosine B absorption spectrum shifts for quantitative determination of octreotide and bromocriptine in their pure forms and pharmaceutical formulations. Evaluation of the method greenness

Article

Author: Abdulrazik, Shrouk G ; Attia, Tamer Z ; Attia, Tamer Z. ; Derayea, Sayed M. ; Abdulrazik, Shrouk G. ; Derayea, Sayed M

In the present study, two drugs for treating acromegaly are investigated which are either synthetic growth hormone inhibiting hormone (GHIH) or dopamine receptor agonist. Octreotide (OCT) and bromocriptine (BCT) were quantified with a quick, simple, and sensitive spectrophotometric approach in their authentic forms and commercial dosage forms. This approach was based upon formation of ion pair complex between erythrosine B and investigated drugs in an aqueous buffered solution. For OCT determination the higher sensitivity was obtained using ΔA at 525 nm. On the other hand, BCT was estimated using the absorbance at 556 nm. Under optimal conditions for the reaction, construction of calibration curves were performed within concentration range of 0.4-4 µg ml^-1 for OCT and 1-9 µg ml^-1 for BCT with with low detection limits (0.094 and 0.235 µg ml^-1) and low quantitation limits (0.29 and 0.71 µg ml^-1) for OCT and BCT respectively. The developed approach was assessed for linearity, accuracy, precision, limits of detection, and limits of quantitation in compliance with ICH validation recommendations. The suggested approaches demonstrated good linearity, as evidenced by determination coefficients (r²) of 0.999 with a slope 0.14 for OCT and 0.9989 with a slope 0.06 for BCT. Additionally, the environmental friendliness of the investigated method was assessed with some of the recent green analytical chemistry metrics.

01 Dec 2024·Cellular Signalling

Octreotide protects against LPS-induced endothelial cell and lung injury

Article

Author: Kubra, Khadeja-Tul ; Fakir, Saikat ; Barabutis, Nektarios

Growth hormone (GH) is a crucial regulator of growth, cell reproduction, and regeneration; and it is controlled by growth hormone-releasing hormone (GHRH) and somatostatin. Lipopolysaccharides (LPS) can compromise endothelial function, leading to increased inflammation and vascular leak. Octreotide (OCT) is an FDA-approved synthetic somatostatin analog (SSA) used to treat acromegaly and neuroendocrine tumors. The present study investigates the effects of OCT on LPS-induced injury in bovine and human lung endothelial cells, as well as in mouse lungs. Our in vitro observations suggest that OCT effectively counteracts LPS-induced endothelial leak, inflammation, and reactive oxygen species (ROS) generation. Furthermore, OCT reduces bronchoalveolar lavage fluid (BALF) protein concentration in an experimental model of Acute Lung Injury (ALI). Our study suggests that OCT mitigates LPS-induced endothelial cell and lung injury, suggesting that it may represent an exciting therapeutic possibility in diseases related to barrier dysfunction.

01 Nov 2024·American Journal of Physiology-Gastrointestinal and Liver Physiology

Somatostatin peptides prevent increased human colonic epithelial permeability induced by hypoxia

Article

Author: Rajput, Ibrahim ; Rajendran, Vazhaikkurichi M. ; Lodge, J. Peter A. ; Nickerson, Andrew J. ; Sandle, Geoffrey I.

Somatostatin (SOM, 2 µM) and octreotide (OCT, 0.2 µM, a long-acting synthetic analog of SOM) were equally effective in preventing chemical hypoxia-induced increases in paracellular shunt permeability/conductance in isolated human colon. In rat distal colon, chemical hypoxia significantly increased total epithelial conductance and transepithelial movement of FITC-dextran 4000, changes completely prevented by 0.2 µM OCT. OCT may prevent or limit gut ischemia during abdominal surgery, thereby decreasing the risk of bacterial/bacterial toxin translocation and sepsis.

100 Deals associated with Maxacalcitol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01098	-	A11CC	DB06272

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Psoriasis	JP	Chugai Pharmaceutical Co., Ltd.	08 Dec 2008
Impetigo	JP	Maruho Co., Ltd.	25 Nov 2008
Ichthyosis	JP	Maruho Co., Ltd.	20 Jun 2001
Keratoderma, Palmoplantar	JP	Maruho Co., Ltd.	20 Jun 2001
Psoriasis vulgaris	JP	Maruho Co., Ltd.	20 Jun 2001
Hyperparathyroidism, Secondary	JP	Chugai Pharmaceutical Co., Ltd.	03 Jul 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01341782 (CTgov)	Phase 3	Hyperparathyroidism, Secondary \| Chronic Kidney Diseases	255	paricalcitol+maxacalcitol placebo (Paricalcitol)	kkatqqhame(zqiowapyxo) = vamcxkjqjl pmpybsbqjs (mznxyfgghn, xjnkenowfv - aljvfxlzay) View more	-	06 Jun 2013
				paricalcitol placebo+maxacalcitol (Maxacalcitol)	kkatqqhame(zqiowapyxo) = bwhimwzdhc pmpybsbqjs (mznxyfgghn, fspjbzulaz - yvzzdowdtr) View more